DGDonata Grimm

Donata Grimm

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Donata Grimm has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Current Treatment Practices and Prognostic Factors in Early-Stage Ovarian Cancer—An Analysis of the NOGGO/JAGO

    by Sabine Heublein, Joanna Baum, Anna Jaeger, Donata Grimm-Glang, Julia Olthoff, Elena Ioana Braicu, Osama Azzam Nieto, Kathrin Hassdenteufel, Barbara Schmalfeldt, Lars Hanker, et al.

    Background: Surgery is the backbone of early-stage ovarian cancer (OC) management. However, in practice, there is disagreement about the extent of surgical staging and whether additional adjuvant treatment should be provided. As omitting relevant diagnostic or therapeutic procedures might lead to undertreatment, we aimed to structurally investigate treatment practice in addition to prognostic factors in a multicentre series of patients (pts) diagnosed with early-stage OC. Patients: Within this retrospective, multicentre study, medical records of 379 pts who had undergone surgery for suspected early-stage OC between January 2014 and March 2020 were analysed. Results: Of the 379 patients, 292 had pT stage 1a-2a and had complete data on the extent of surgical staging. At least one surgical step was omitted in 100 pts (34.2%). Complete surgical staging (n = 192; (65.8%)) was more often performed in high-grade serous OC and was independent of the healthcare level of the hospital where the initial diagnosis was made. Missing to take peritoneal biopsies was associated with reduced relapse-free-survival in incompletely staged, pT1 cases (p = 0.03). About every second patient (46.7%) with a final stage lower than FIGO IIB and treated with adjuvant chemotherapy received combination chemotherapy. BRCA1 and BRCA2 testing was only performed in a subset of pts, and mutations were detected in 18% (14/79) and 9% (7/85) pts, respectively. Conclusions: This study helps to increase our understanding of early-stage OC treatment and prognosis. In addition to treating patients in compliance with current guidelines, the need for BRCA testing should also be considered for early-stage OC.


  • Course of cervical intraepithelial neoplasia diagnosed during pregnancy

    by Donata Grimm, Isabelle Lang, Katharina Prieske, Anna Jaeger, Volkmar Müller, Sascha Kuerti, Eike Burandt, Susanne Lezius, Barbara Schmalfeldt, Linn Woelber

    Purpose Management of high-grade cervical intraepithelial neoplasia [CIN grade 2 or 3 (CIN2–3)] diagnosed during pregnancy is controversial. Monitoring with colposcopy and cytology every 8–12 weeks is advised by the most current guidelines. Study design This study analyzes the course of disease in pregnant women with abnormal cytologies or clinically suspicious cervixes. Results In total, 139 pregnant women, at a median age of 31 years (range 19–49), treated at the Colposcopy Unit of the University Medical Center Hamburg-Eppendorf between 2011 and 2017 were identified. During pregnancy, at least one biopsy was performed on 70.5% of patients. In 84.7% of cases, CIN2–3 (CIN2 n = 14 (14.3%), CIN3 n = 69 (70.4%)) was detected, 7.1% (n = 7) of women were diagnosed with CIN1, while no dysplasia was found in 8.2% (n = 8) of cases. No interventions were necessary during pregnancy. Despite explicit invitation, only 72.3% of women with CIN2–3 attended postpartal consultations. While 61.7% showed persistent lesions, 5% were diagnosed with CIN1 and 33.3% with complete remission. During pregnancy, 68.7% of women with prepartal CIN2–3 were tested for HPV infection. Later, 49.1% were followed up postpartally by means of HPV testing and histology. HPV clearance was observed in 36.4% of women with complete histological remission. Postpartum conization was performed on 44.6% of patients with prepartal CIN2–3 diagnosis. CIN2–3 was histologically confirmed in 97.3% cases. Progression from persistent CIN3 to microinvasive carcinoma was observed in a single case. Conclusions High-grade CIN lesions, diagnosed during pregnancy, show a high rate of regression postpartum; whereas, progression to carcinoma is rare. Close and continuous monitoring rarely has any therapeutic consequences. Compliance for postpartal follow-up needs to be improved.


  • Superficially invasive stage IA vulvar squamous cell carcinoma—therapy and prognosis

    by Donata Grimm, Katharina Prieske, Sabrina Mathey, Sascha Kuerti, Eike Burandt, Barbara Schmalfeldt, Linn Woelber

    Objectives Superficially invasive stage IA squamous vulvar cancer (VSCC) is defined as a single lesion measuring ≤2 cm with a depth of invasion of ≤1.0 mm (FIGO stage IA). This article examines the natural course and prognosis of superficially invasive VSCC. Methods This is a retrospective case series of 46 patients (median age 58 years) with superficially invasive stage IA VSCC receiving wide local excision between January 1996 and November 2014 in the University Medical Center Hamburg-Eppendorf. Results Median tumor size was 4 mm. In 39/46 (84.8%) patients peri-tumoral high-grade intraepithelial neoplasia (HSIL) and/or lichen sclerosus (LS) of the vulva were histologically detected: 34 (74.0%) usual type high-grade vulvar intraepithelial neoplasia (uVIN, HSIL), 4 (8.7%) LS with simultaneous VIN (3 uVIN, 1 differentiated VIN (dVIN)), 1 (2.2%) with LS only. 37/46 (80.4%) patients had a R0 resection; in 2 (4.3%) a high-grade VIN was detected in the margin and in 7 (15.2%) the resection status was unknown. The mean follow-up was 58 (range 10–185) months. Four patients (8.7%) suffered from an invasive recurrence after 4, 17, 40, and 54 months, three in the vulva and one in the groin. All local recurrences occurred in women with LS in a combination with high-grade VIN (3 uVIN, 1 dVIN). Two were treated surgically again including inguino-femoral lymphadenectomy (ifLAE) (no regional lymph node metastasis histologically) as invasion depth exceeded 1 mm. The third patient refused treatment. Inguinal recurrence was treated with a bilateral ifLAE, revealing one positive lymph node, followed by adjuvant radiotherapy (groins, pelvis). None of these patients had experienced further recurrences at last follow-up. Conclusions Superficially invasive VSCC is characterized by having a very good prognosis. Sole surgical therapy is highly effective. Patients with LS might benefit additionally from intensified surveillance and adequate maintenance therapy in specialized centers.


  • Oral Human Papillomavirus in Women With High-Grade Cervical Intraepithelial Neoplasia

    by Linn Woelber, Julia Breuer, Thomas Meyer, Eik Vettorazzi, Katharina Prieske, Inga Bohlmann, Chia-Jung Busch, Ingo Teudt, Oliver Brummer, Volkmar Mueller, et al.

    Objective: This study was designed to investigate the co-prevalence of cervical and oropharyngeal human papillomavirus (HPV) infection in patients with HPV-related high-grade disease of the uterine cervix (high-grade squamous intraepithelial lesion [HSIL]).Materials and Methods: In a prospective cohort study, women with abnormal cervical cytology admitted to our colposcopy units received HPV testing of the uterine cervix and the oropharynx via smear. From a subset of patients, oral lavage was collected to compare detection rates of HPV DNA between lavage and swab. Patients with confirmed high-risk HPV (HR-HPV)–positive HSIL of the cervix were further investigated. Sexual behavior and lifestyle factors were documented with a standardized questionnaire.Results: Two hundred thirty-five women were included in the study. Of the 235 women, 135 (57.5%) were cervically HR-HPV positive with histologically confirmed high-grade cervical intraepithelial lesion (median [range] age = 30 [21–45] years). Of these, only 6 (4.4%) also had a positive oral specimen. In 3 (50%) of the 6 cases, the same HPV type was detected in oral and cervical samples (HPV 16, 35, and 45). Oral HPV detection was not higher when combining swab and lavage compared with swab alone. A relation between sexual behavior and oral HPV detection could not be demonstrated.Conclusions: Oral HPV prevalence in women with cervical HPV infection and HSIL is low. Simultaneous testing of oropharyngeal and cervical HPV infection does not seem promising as future screening strategy.


  • Correlation of isotope count with sentinel node positivity in vulvar cancer.

    by Linn Lena Woelber, Simon Joosse, Donata Grimm, Sven Mahner, Eike Burandt, Barbara Schmalfeldt, Susanne Klutmann, Katharina Prieske

    E17033 Background: Sentinel node biopsy (SNB) has become standard of care in early stage vulvar cancer. As the correlation of isotope count with the presence of metastases remains unclear, often several active nodes are excised per groin. This can result in increased morbidity in node-negative disease despite of SNB. In the current analysis we assess, whether resection of the hottest node could be sufficient to detect sentinel lymph node (SNL) metastasis. Methods: All patients with primary vulvar cancer receiving a SNB with radioactive tracer at the University Medical Center Hamburg-Eppendorf between 2008 and 2015 were evaluated. The day before surgery, patients received four peritumoral intradermal deposits at 3, 6, 9 and 12 o’clock with an overall mean dosage of 85±12MBq99mTc–nanocolloid. Planar lymphscintigraphy was performed one hour after injection. Intraoperatively, a handheld gamma counter was used to identify the SNL. Results: 146 patients with SNB were included; thereof 145 pts underwent bilateral SNB, resulting in 291 analyzed groins. A median of 2 (range 1-7) SNL per groin were removed. From 95/291 (32.6%) groins more than 2 SNL were excised. Median overall SNL isotope count was 1400. In 52 groins, a positive SNL was detected (unilateral in 38 patients, bilateral in 7). The median number of positive SNL per groin was 1 (range 1-4). There was no difference of median count in negative compared to positive SNL (median count 1396 vs. 1614; p=0.90). The SNL with the highest isotope count carried metastases in 36/48 groins (75.0%; in 4 cases the highest count was unknown). In 12/48 (25.0%) positive groins, the SNL with the highest count was not the metastatic SNL (11/12 second highest count). Median count of these 12 SNL was 58.8% of the highest count with a range from 6.0% to 74.0%. Conclusions: The highest isotope count does not reliably detect the positive SNL in vulvar cancer. To prevent mostly fatal groin recurrences, surgeons should continue to remove all SNL accumulating relevant radioactive tracer over minimal background activity.

  • Participation of elderly gynecological cancer patients in clinical trials.

    by Katharina Prieske, Fabian Trillsch, Gulten Oskay-Oezcelik, Radoslav Chekerov, Eva-Maria Schoening, Leticia Oliveira-Ferrer, Donata Grimm, Sasha Kuerti, Anna Suling, Barbara Schmalfeldt, et al.

    E21520 Background: Elderly patients (pts) are underrepresented in clinical trials in gynecological cancer, even though they are disproportionally often affected. This study aimed to evaluate disposition and apprehension of elderly pts towards study participation. Methods: 112 elderly gynecological cancer pts (median age 70; range 65-92) were surveyed in a multicenter cross-sectional study. Besides fitness, state of disease, education and domestic situation, questions aimed at the general willingness to participate in a clinical trial. Personal reasons for rejection and suspected advantages/disadvantages that might evolve from participation were inquired. Results: Willingness to participate in a study was generally high (66.1%, 74/112). 42/112 (37.5%) had given their consent to participation in a study before, 12.5% (6/48) refused even though they were offered participation. Reasons for potential study participation were: ‘better monitoring of the disease’ (51/112), ‘better medical care’ (35/112), ‘to help medical research’ (31/112), ‘better medication’ (27/112) and ‘because of my doctor’s recommendation’ (17/112). Reasons for potential refusal were: ‘too time consuming’ (19/112), ‘fear of side effects’ (17/112), ‘misuse as experimental animal’ (14/112), ‘long distance to clinic’ (11/112) and ‘too little or unclear information’ (7/112). 26.1% (29/112) of pts stated, that they had ‘no objection’ against study participation. The question if pts anticipated having a longer life due to study participation was answered with ‘yes’ or ‘rather yes’ in 33.9% (38/112), 23.2% answered ‘no’ or ‘rather no’ (23.2% undecided). No relation between willingness to participate in a study and general fitness (p = 0.311), education (p = 0.631) or domestic situation (p = 0.195) could be observed. However, with increasing age, willingness decreased (p = 0.029). Conclusions: Elderly pts are generally willing to participate in clinical studies regardless of their fitness or educational background. Benefits of participation seem to be unclear among a majority of potential study participants. Therefore it might be decisive to provide more general information regarding benefits and safety for the elderly pts in a clinical trial.